These are top 10 stocks traded on the Robinhood UK platform in July
Dermata Therapeutics Inc. (DRMA) stock has reached a new 52-week low, trading at $0.69, as the company faces a challenging market environment. According to InvestingPro data, the company maintains a healthy current ratio of 3.7x and holds more cash than debt, though its overall financial health score remains weak at 1.55. This latest price point underscores a significant downturn for the biotechnology firm, which has seen its stock value plummet by 81.77% over the past year. Investors are closely monitoring Dermata’s performance, as the company navigates through a period marked by investor skepticism in the biotech sector, potentially undervalued assets, and a heightened focus on the company’s pipeline and strategic initiatives. With analysts setting a $3 price target and InvestingPro analysis suggesting the stock is currently undervalued, the 52-week low serves as a critical indicator for both the company and its stakeholders, as it reflects the market’s current valuation of Dermata’s prospects and operational progress. (Discover 10+ additional exclusive insights and real-time metrics with InvestingPro.)
In other recent news, Dermata Therapeutics has reported significant progress in its clinical trials for XYNGARI™, a once-weekly topical acne treatment. The Phase 3 STAR-1 trial demonstrated statistically significant improvements in both inflammatory and non-inflammatory acne lesions, with 29.4% of patients achieving a clear or almost clear skin rating compared to 15.2% in the placebo group. This trial success sets the stage for the upcoming Phase 3 STAR-2 trial, expected to begin in the fourth quarter of 2025. Dermata has also started drug production for this trial, aiming for topline results in the first half of 2027. Additionally, Maxim Group has adjusted its price target for Dermata to $3.00, down from $6.00, while maintaining a Buy rating, following the company’s recent financial disclosures and clinical trial updates. Dermata reported a cash reserve of $9.7 million as of March 31, 2025, with no debt, and anticipates a potential capital raise later in 2025. The company’s forward-looking plans include a new drug application submission to the FDA if the STAR-2 trial proves successful. Dermata continues to explore XYNGARI™ for additional skin conditions like psoriasis and rosacea.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.